C1513528||Glucagon-CreER mouse line
C0242613||gene targeting
C0030280||α-cells
C0449475||cell type
C0022131||pancreatic islets
C0017687||glucagon
C0455280||plasma glucose levels
C0015663||fasting
C0030280||α-cell
C0017687||glucagon
C0036536||secretion
C0011854||type 1
C0011860||type 2 diabetes
C0030280||α-cells
C1513384||gene ablation
C0017255||activation
C0030280||α-cells
C0030281||β-cells
C1513528||Glucagon-Cre
C1513528||Glucagon-CreER transgenic mouse lines
C0282641||transgene
C0598496||silencing
C1513528||Glucagon-CreER "knock-in" mouse line
C0017687||glucagon
C2936267||haploinsufficiency
C1294202||gene deletion analyses
C1513528||Glucagon-CreER(T2) mouse line
C1333664||glucagon
C1171362||expression
C0282641||transgene
C0598496||silencing
C1512886||IRES-CreER(T2) sequence
C0600600||3' UTR
C1333664||Glucagon
C1333664||Glucagon
C0678933||locus
C4042879||mouse embryonic stem cells
C4042879||embryonic stem cells
C4042879||ESC
C0009013||clones
C0025929||mouse
C1281743||blastocysts
C0025936||Gcg-CreER(T2) mice
C0034865||Recombination
C0017687||GCG
C0030280||pancreatic α-cells
C0061355||glucagon-like peptide 1 positive
C0061355||glucagon-like peptide 1 positive
C2333553||enteroendocrine L-cells
C0025936||Gcg-CreER(T2)
C0025936||Rosa26-LSL-YFP mice
C0021485||injected
C0039286||tamoxifen
C0015928||fetal development
C0039286||Tamoxifen
C0021485||injection
C0025936||Gcg-CreER(T2)
C0025936||Rosa26-LSL-YFP mice
C0034865||recombination
C0678933||Rosa26-LSL-YFP locus
C0030280||α-cells
C0030280||α-cells
C2333553||enteroendocrine L-cells
C0025929||Mice
C0017337||Gcg-CreER(T2)
C0002085||allele
C1513528||Gcg-CreER(T2) mouse line
C0017262||expresses
C0017337||CreER(T2)
C0030280||pancreatic α-cells
C2333553||enteroendocrine L-cells
C1333664||preproglucagon
C0017262||gene expression
C0025929||mice
C0449475||cell types